A PARP inhibitor in oral tablet form, given in combination with chemotherapy, was deemed safe for heavily pretreated patients with ovarian cancer.
A new use for an old drug shrinks a particular type of pancreatic cancer and stops it from spreading, according to new research.
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.
A gel containing the drug tamoxifen and applied to the skin was as effective as the pill form in reducing the growth of breast cancer cells in women with noninvasive cancer.
The addition of MM-398, a novel nanoliposome formulation of irinotecan, to standard treatment improves survival for metastatic pancreatic cancer patients who have already received gemcitabine.
A new combination of medications for treatment of recurrent ovarian cancer showed improved response rates, increased the rate of tumor shrinkage, and prolonged the time until cancers recurred
Nanomedicine technologies were utilized to develop a drug-delivery system that precisely targets and attacks cancer cells in the bone. It also increases bone strength and volume to prevent bone cancer progression.
A high-risk group of patients with follicular lymphoma could benefit from a novel drug combination, according to a new study published in the Journal of Experimental Medicine.
Five drug companies, the government, private foundations, and advocacy groups have come together to try a bold new way for testing cancer drugs. Described as a medical version of speed dating, physicians will sort through multiple experimental drugs and match patients to the one most likely to succeed.
Many older breast cancer patients with localized disease are taking drug treatments to prevent their cancer from returning, a new study finds. The research, covering a 7-year period, included more than 1,000 women, age 65 to 91 years, across the United States who had estrogen-positive breast cancer that had not spread.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.
Among patients with non-small cell lung cancer treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes.
The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.
The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.
In women with breast cancer, loss of the tumor suppressor PTEN was a frequent cause of resistance to the investigational drug BYL719, which blocks the activity of a protein called PI3K-alpha.
The quest to improve survival of children with a high-risk brain tumor has led investigators to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers.
A new drug, ceritinib, appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.
A patient with advanced bladder cancer experienced a complete response to the drug combination everolimus and pazopanib in a phase 1 clinical trial. Genomic profiling revealed information that could help identify other patients who may respond to everolimus and pazopanib.
A German study of a new drug therapy for chronic lymphocytic leukemia (CLL) was lauded for including elderly persons who had other, coexisting health issues. An accompanying editorial noted that the study population more accurately represented patients with CLL.
What can nurses do to advocate for the use of medications such as lorezepam (Ativan) for anticipatory nausea when the physician is reluctant to prescribe antianxiety or sleep medications?
Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to an early-phase clinical trial.
Patients requesting specific medications are more likely to be prescribed those medications, according to research.
Researchers have discovered that FDA-approved antipsychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.
A never-before-seen autophagy mechanism induced by the BRAF inhibitors vemurafenib and dabrafenib explains the resistance that melanoma develops to these BRAF inhibitors, according to new research.
In research that could ultimately lead to many new medicines, scientists have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
By screening a library of US FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, scientists were surprised to find several potential possibilities.
Many patients skip doses or stop taking medication entirely when their share of the costs becomes too high.
Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|